Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.
- Medicine, BiologyAllergology international : official journal of the Japanese Society of Allergology
The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
- MedicineInternal and Emergency Medicine
Both clinical features, disease activity, and treatments appear to be significantly different between EGPA subgroups, although the relapse risk was similar although clinical features and treatment strategies were different.
Renal Involvement as Rare Acute Tubulointerstitial Nephritis in a Patient with Eosinophilic Disorder Treated with Early Add-on Administration of Mepolizumab
- MedicineInternal medicine
The revised classification of EGPA based on the etiology should dictate the proper treatment in suspected EGPA patients with nonsystemic vasculitis.
Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.
- MedicineThe Journal of asthma : official journal of the Association for the Care of Asthma
Mepolizumab 100 mg provided a significant decrease in SNOT-22 values, especially in nasal and sleep domains, eosinophil counts and OCS dose in the 6th month.
Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs
- Medicine, BiologyImmunopharmacology and immunotoxicology
The mechanism of immunosuppressants, new agents' discovery, and current therapeutic protocols in the transplantation are discussed, and the importance of individualized drug use is shown.
- MedicinePresse medicale
SHOWING 1-10 OF 105 REFERENCES
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review
- Medicine, BiologyDrugs
Characteristics of eosinophilic granulomatosis with polyangiitis are reviewed and an overview of established and novel pharmacological agents is provided.
Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis.
- Medicine, BiologyAutoimmunity reviews
Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- MedicineClinical Rheumatology
A 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment is reported, who was treated with rituximab, which enabled rapid control of the Vasculitis component of the disease, but there was no response to rhinococci and asthma.
Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome
- Medicine, BiologyAnnals of the rheumatic diseases
Attention is drawn to the potential risk of rituximab-associated bronchospasm, by reporting that therapy-refractory CSS5 was successfully treated with ritUXimab in three patients, and the potential role of B lymphocytes plays a role as antigen-presenting cells and can modulate the immune response in another way than targeting antibody production.
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- MedicineArthritis Research & Therapy
Preemptive retreatment with RTX, combined with standard maintenance immunosuppressants, resulted in a sustained treatment response and rituximab proved to be an efficient and safe treatment for AN CA-positive and ANCA-negative patients.
Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.
- Medicine, BiologyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
In this pilot study, RTX was safe and successful in controlling renal disease activity in three patients with CSS and deserves further study in CSS.
Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
- MedicineAnnals of the rheumatic diseases
The treatment of EGPA with rituximab resulted in high rates of improvement and reduced requirement of prednisolone, and may be considered for the treatment ofEGPA.
Churg-Strauss syndrome successfully treated with rituximab
- MedicineRheumatology International
Two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity are described.